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Abstract
The classical approach to analyze pharmacokinetic (PK) data in bioequivalence studies
aiming to compare two different formulations is to perform noncompartmental analysis
(NCA) followed by two one-sided tests (TOST). In this regard the PK parameters AUC
and Cmax are obtained for both treatment groups and their geometric mean ratios are
considered. According to current guidelines by the U.S. Food and Drug Administration
and the European Medicines Agency the formulations are declared to be sufficiently similar
if the 90%- confidence interval for these ratios falls between 0.8 and 1.25. As NCA is not
a reliable approach in case of sparse designs, a model-based alternative has already been
proposed for the estimation of AUC and Cmax using non-linear mixed effects models. Here
we propose another, more powerful test than the TOST and demonstrate its superiority
through a simulation study both for NCA and model-based approaches. For products
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with high variability on PK parameters, this method appears to have closer type I errors
to the conventionally accepted significance level of 0.05, suggesting its potential use in
situations where conventional bioequivalence analysis is not applicable.
Keywords and Phrases: bioequivalence, nonlinear mixed effects model, pharmacokinetics, non-
compartmental bioequivalence analysis, two one-sided tests
1 Introduction
In drug development the comparison of two different formulations of the same drug is a fre-
quently addressed issue. In this regard bioequivalence studies investigating the difference be-
tween two treatments are performed. According to current guidelines by the U.S. Food and
Drug Administration (2003) and the EMA (2014) this question is commonly addressed by com-
paring the ratios of the geometric means of the pharmacokinetic (PK) parameters area under
the curve (AUC) and the maximal concentration (Cmax) to a prespecified threshold. More
precisely, bioequivalence is established if the boundaries of the 90%-confidence intervals for
these ratios fall between 0.8 and 1.25 which is equivalent to performing two one-sided tests
(TOST) proposed by Schuirmann (1987). As the data are usually log-transformed, we consider
the log-ratio (also defined as the treatment effect) and hence the commonly used equivalence
margin is given by δ = log(1.25).
When performing bioequivalence studies, the classical approach to analyze PK data is given by
noncompartmental analysis (NCA), see for example Gabrielsson and Weiner (2001), followed
by a linear mixed effect analysis of the AUC or Cmax. The advantage of this approach is
that it is very simple and comes without any further assumptions or knowledge of the data.
However, it requires a sufficiently large number of samples and subjects which cannot be pro-
vided in each trial. As pointed out by Dubois et al. (2011) and Hu et al. (2004) the estimates
obtained by NCA are biased if these conditions are not fulfilled. Further, in numerous studies a
sufficiently large number of samples cannot be guaranteed. For instance, in pediatric research,
ethical considerations lead to difficulties in the planning of studies which are therefore typically
very small in size (for an example see Mentre´ et al. (2001)). But also in other areas where
patients are especially frail, as for example in cancer research, these requirements are often
not met and therefore methods for sparse designs are required. In such situations the Nonlin-
ear Mixed Effects Models (NLMEM) have become very popular for analyzing pharmacokinetic
data (see Sheiner and Wakefield (1999)). NLMEM turned out to be a promising alternative to
the classical approach as the estimation of individual effects allows for incorporating variabil-
ities, as the Between-subject-variability (BSV) and the Within-subject-variability (WSV), for
a detailed comparison see Pentikis et al. (1996); Combrink et al. (1997); Panhard and Mentre´
(2005). Consequently the main advantage of the NLMEM consists in the improved accuracy of
the estimates in particular when dealing with sparse designs (see also Hu et al. (2004)).
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In order to assess bioequivalence between two products typically the two one-sided tests (TOST)
proposed by Schuirmann (1987) is performed, where two level α-tests are combined for testing
two seperate sub-hypotheses. This method is based on the Intersection-Union Principle (see
Berger (1982)) and one concludes bioequivalence if for both one-sided tests the null hypotheses
can be rejected. Due to its simplicity, this approach which is still recommended in the FDA
guidelines has become very popular and is common practice nowadays (see for example Bristol
(1993), Brown et al. (1997) and Midha and McKay (2009) among many others). However,
it was demonstrated by Phillips (1990) and Tsai et al. (2014) that for a small number of in-
dividuals, high variability in the data or only few samples per patient this method is rather
conservative and suffers from a lack of power.
The present paper addresses this problem. Here we propose a new model-based approach for the
assessment of bioequivalence which turns out to have always more power than the corresponding
TOST. The superiority of the new approach is particularly visible in situations with a large
variability in the data in parallel designs. The motivation of the new methodology is given
by the uniformly most powerful test for normally distributed data with known variance, which
can be found in many text books on mathematical statistics (see for example, Lehmann and
Romano (2006), or Wellek (2010)). We argue that the superiority of this methodology for NCA
also carries over to model-based inference for reasonable large sample sizes and demonstrate
this fact by means of a simulation study.
This paper is organized as follows. In Section 2 we present the classical problem of bioequiva-
lence and review two tests for this problem, including the commonly used TOST for NCA-based
inference. In Section 3 we introduce the NLMEM, then we present the model based TOST as
first introduced by Panhard and Mentre´ (2005) and Dubois et al. (2011) and after that the
new model based approach. Subsequently, these tests are compared by means of a simulation
study in Section 4 with NCA-based tests both for parallel and cross-over designs varying BSV
and WSV. In particular we demonstrate that the new approach (model and NCA-based) usu-
ally yields larger power than methodology based on the TOST. Some theoretical arguments
for these finding can be found in the Appendix, where we review properties of both methods
in the problem of comparing the means from two normal distributions with known variance.
This scenario corresponds to some kind of asymptotic regime for the problems considered in
practice, if the sample sizes are reasonably large.
Summarizing, the new approach introduced in the present paper improves the commonly used
TOST for bioequivalence testing based on NCA or model-based inference. It has never lower
power than this test, but substantially larger power in scenarios with a large variability in
parallel designs.
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2 Review of bioequivalence tests
In this section we will briefly review a commonly used approach for bioequivalence testing,
which is based on the well-known two one-sided test (TOST) introduced by Schuirmann (1987).
We further present another more powerful method for testing bioequivalence (see for example
Wellek (2010)) which gives the motivation for the newly developed model-based test in Section
3.3. For the sake of simplicity, both methods are described here in the case of a two groups
parallel design, but can be applied to crossover design, more standard in BE.
In a bioavailability/bioequivalence study a test (T) and a reference product (R) are adminis-
tered and it is investigated whether the two formulations of the drug have similar properties
with respect to average bioavailabilty in the population. Exposure, in this context, is usually
characterized by blood concentration profile variables and summarized by the area under the
time concentration curve (AUC) and the maximum concentration (Cmax). More precisely, let
µT and µR denote the average means of the test and reference product for logAUC or logCmax,
then the common testing problem in bioequivalence is defined by the hypotheses
H0 : |µT − µR| ≥ δ vs. H1 : |µT − µR| < δ, (2.1)
where δ is a given threshold. For example, according to the 80/125-rule considered in the
guidelines by EMA (2014) and U.S. Food and Drug Administration (2003) the threshold δ is
given by δ = log (1.25).
For the problem of testing for PK bioequivalence the metrics of interest are given by AUC and
Cmax, which means that we consider
βTAUC := µT − µR = logAUCT − logAUCR
βTCmax := µT − µR = logCmax,T − logCmax,R (2.2)
in (2.1), where βTAUC and β
T
Cmax
are the treatment effects on AUC and Cmax respectively.
2.1 The two one-sided Tests (TOST)
We consider the following sub-hypotheses of H0 as described in (2.1) given by
H0,−δ : µT − µR ≤ −δ and H0,δ : µT − µR ≥ δ. (2.3)
The idea of the TOST consists in testing each of these hypotheses separately by a one-sided
test. The global null hypothesis H0 in (2.1) is rejected with a type I error α if both one-
sided hypotheses are rejected with a type I error α. To be precise let XT,1, . . . XT,NT and
XR,1, . . . XR,NR denote the samples from the test (T) and a reference product (R) respectively
and denote by X¯k =
1
Nk
∑Nk
i=1Xk,i (k = R, T ) the mean measured endpoints (over all individuals
for the two treatments). Under the assumption that the random variables {Xk,i : i =
4
1, . . . Nk, k = R, T} are independent and normally distributed with a common (but unknown)
variance σ2, that is XR,i ∼ N (µR, σ2); i = 1 . . . , NR , XT,i ∼ N (µT , σ2); i = 1 . . . , NT we have
for the corresponding means
X¯R ∼ N (µR, σ2NR ) and X¯T ∼ N (µT , σ
2
NT
). (2.4)
In applications XR,i and XT,i usually represent AUCk and Cmaxk , k = R, T , which are typically
assumed to be lognormally distributed (see Lacey et al. (1997)). We denote by σ2P :=
(
1
NR
+
1
NT
)
σ2 the pooled variance and by d := µT − µR the difference between the expectations of the
reference and the treatment group. This yields for the difference of the means
X¯T − X¯R ∼ N (d, σ2P ). (2.5)
The unknown variance σ2P is estimated by
σˆ2P :=
(
1
NT
+ 1
NR
)
σˆ2, (2.6)
where
σˆ2 =
1
NT +NR − 2
∑
k∈{R,T}
Nk∑
i=1
(
Xk,i − X¯k
)2
.
Consequently the null hypothesis in (2.1) is rejected if
X¯T − X¯R − (−δ)
σˆP
≥ tN−2,1−α and X¯T − X¯R − δ
σˆP
≤ −tN−2,1−α, (2.7)
where tN,1−α is the (1 − α)-quantile of the t-distribution with N − 2 = NR + NT − 2 degrees
of freedom (see for example Chow and Liu (1992)). This method is equivalent to constructing
a (1 − 2α)-confidence interval for µT − µR and concluding bioequivalence if its completely
contained in the equivalence interval [−δ, δ] (see Schuirmann (1987)).
The approach presented above has been extended for model-based bioequivalence inference by
Dubois et al. (2011) and will be explained in detail in Section 3.2.
2.2 An efficient alternative to TOST
In this section we will review an alternative test which is (asymptotically) the most powerful
test in this setting. In the case of known variances this property is well known in the literature
on mathematical statistics (see, for example, Romano et al. (2005)), and, for the sake of com-
pleteness, a proof of optimality will be given in the Appendix A.2, where we also review some
aspects of the power of the TOST. These considerations motivate the model-based method,
which we will propose in the following Section 3.3.
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To be precise, let NF (d, σ2P ) denote the folded normal distribution with parameters (d, σ2P ),
that is the distribution of the random variable |Z|, where Z ∼ N (d, σ2P ). Due to (2.5) we have
for the absolute difference ∣∣X¯T − X¯R∣∣ ∼ NF (d, σ2P ).
This result motivates the choice of the quantile determining the decision rule of the test, which
is described in the following algorithm.
Algorithm 2.1. (A more powerful test)
1. Estimate the parameters of interest µˆR and µˆT by X¯R and X¯T (for instance by non-
compartmental analysis) and estimate the variance of the difference X¯T − X¯R by the
statistic defined in (2.6).
2. Reject the null hypothesis, whenever∣∣X¯T − X¯R∣∣ < uˆα, (2.8)
where uˆα is the α-quantile of the folded normal distribution NF (δ, σˆ2P ).
The quantile uˆα can be calculated solving the equation
α = Φ
(
1
σˆP
(u− δ)
)
− Φ
(
1
σˆP
(−u− δ)
)
.
Alternatively, it can directly be obtained by using statistical software, as for example the
V GAM package by Yee (2015) in R.
The approach presented in Algorithm 2.1 is extended in Algorithm 3.1 for model-based bioe-
quivalence inference, where we will estimate the parameters of interest µˆR and µˆT by fitting a
nonlinear mixed model to the data.
2.3 Noncompartmental analysis
If we are testing for PK bioequivalence considering the hypotheses in (2.2) we need to calculate
estimates of AUC and Cmax directly from the data. In this regard the classical approach is given
by NCA, as described for example in Gabrielsson and Weiner (2001). More precisely, Cmax is
directly obtained from the data, whereas AUC is approximated by the linear trapezoidal rule.
This means that the total area under the curve is obtained by separating it into several smaller
trapezoids and summing up these areas. Of course the accuracy of this approach strongly
depends on the number of measurements as this gives the number of trapezoids but it does
not require a model assumption and is widely applicable. As these methods do not take the
profile of the blood concentration-time curve into account, we call them NCA-based methods
throughout this paper and they will be discussed in more detail in Section 3.
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3 Model-based Bioequivalence Tests
Classical NCA-based tests are a useful tool to establish bioequivalence if the blood concentration
profile variables AUC and Cmax can be calculated with a reasonable precision without using
information about the form of the concentration profiles. For this purpose one usually needs a
relatively dense design to determine the area under the curve or the maximum of the profile.
However, there are many situations, where only a sparse design is available (for some examples
see Hu et al. (2004)) and the NCA-based calculation of AUC and Cmax might be misleading as
the estimates are biased in this case (see Dubois et al. (2011)). In such situations where NCA is
not reliable a model-based approach as proposed for the TOST by Panhard and Mentre´ (2005)
and Dubois et al. (2011) might have important advantages.
Roughly speaking they proposed to use non-linear mixed effects models (NLMEM) to describe
the blood concentration profile and derive AUC and Cmax estimates. These quantities are then
further analyzed using the methodology introduced in Section 2. By this approach they were
able to increase the accuracy of bioequivalence tests in the case of sparse designs.
We will use the same methodology to extend the approach presented in Section 2.1 to situations
with sparse designs. This new test achieves more power and simultaneously controls the type
I error.
3.1 Nonlinear mixed effects models (NLMEM)
We first consider crossover trials with K periods and N subjects, investigating the difference
between a test and a reference treatment. A classical situation is given by the (balanced) two-
period, two-sequence crossover design (K = 2), where the N/2 patients receive treatment R
in the first period and treatment T in the second one while the other N/2 patients receive the
treatments in the reverse order.
For each subject concentrations of the drug are measured in all periods and at different sampling
points. In order to represent the dependence of the concentration on time for one subject we
follow Dubois et al. (2011) and use a non-linear function, say f in order to fit one global model
to the data, that is
yi,j,k = f(ti,j,k, ψi,k) + g(ti,j,k, ψi,k)εi,j,k, (4.1)
where yi,j,k denotes the concentration of the i-th subject (i = 1, . . . N) at sampling time ti,j,k
(j = 1, . . . , ni,k) of period k (k = 1, . . . K). In (4.1) the residual errors εi,j,k are indepen-
dent and standard-normally distributed random variables and the function g is used to model
heteroscedasticity. In particular we consider a combined error model with
g(ti,j,k, ψi,k) = a+ b · f(ti,j,k, ψi,k), (4.2)
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where the parameters a, b ∈ R≥0 account for the additive and the proportional part of the error
respectively. This gives for the variance of the errors in (4.1)
Var(yi,j,k) = (g(ti,j,k, ψi,k))
2 = |a+ b · f(ti,j,k, ψi,k)|2.
The individual parameters ψi,k = (ψi,k,1, . . . , ψi,k,p)
> (of length p) are defined by
log(ψi,k,l) = log λl + β
T
l Tri,k + β
P
l Pk + β
S
l Si + ηi,l + κi,k,l, l = 1, . . . , p, (4.3)
where λ = (λ1, . . . , λp)
> denotes a vector of fixed effects, Tri,k, Pk and Si the (known) vectors
of treatment, period and sequence covariates respectively and βT , βP and βS the vectors of
coefficients of treatment, period and sequence effects. In order to account for the variability
between individuals, denoted as between-subject-variability (BSV), and the variability of one
subject between two periods respectively, that is the within-subject-variability (WSV), we
introduce random effects ηi = (ηi,1, . . . , ηi,p)
> and κi,k = (κi,k,1, , . . . , κi,k,p)>. More precisely,
the random effect ηi represents the BSV of subject i and κi,k the WSV of subject i at period k
respectively. Throughout this section we assume that the random effects are normal distributed,
that is
ηi ∼ N (0,Ω), κi,k ∼ N (0,Γ), i = 1, . . . N, k = 1, . . . K, (4.4)
with p× p-dimensional covariance matrices Ω and Γ and denote the diagonal elements of these
matrices by ω2l and γ
2
` , respectively. Finally, the vector of all parameters in model (4.1) is given
by
θ = (λ, βT , βS, βP ,Ω,Γ, a, b). (4.5)
For biologics with a long half-life, such as monoclonal antibodies, a parallel group design, that
is each individual receives only the test or the reference treatment, may be necessary (Dubois
et al. (2012)). In that case, we consider only one period and the WSV can be omitted and (4.3)
simplifies to
log(ψi,l) = log λl + β
T
l Tri + ηi,l, l = 1, . . . , p. (4.6)
Note that in this case we do not assume any period or sequence effects and hence the vec-
tor in (4.5) simplifies to θ = (λ, βT ,Ω, a, b). For the sake of simplicity we now introduce a
vector β which is defined by β := βT in case of parallel designs and β := (βT , βS, βP ) for
crossover designs. Consequently we can write for the vector of all parameters in model (4.1)
θ = (λ, β,Ω,Γ, a, b), where Γ disappears in case of parallel design.
Considering now the hypotheses in (2.2) the treatment effects βTAUC and β
T
Cmax
on AUC and
Cmax respectively can be directly obtained from the parameters of the global NLMEM. In other
words, there exist functions, hAUC, hCmax , such that
βTAUC = hAUC(λ, β), β
T
Cmax = hCmax(λ, β). (4.7)
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By this we obtain an estimate for its variance using the delta method (Oehlert (1992)), which
has been proposed by Panhard et al. (2007). With these notations the hypotheses in (2.1) can
be rewritten as
H0 : |βT | ≥ δ versus H1 : |βT | < δ (4.8)
where we do the same for AUC and Cmax.
3.2 Model-based TOST
A model-based version introduced by Panhard and Mentre´ (2005); Panhard et al. (2007) and
Dubois et al. (2011) of the TOST for bioequivalence can be obtained by fitting the NLMEM
(4.1) to the data and calculate the estimate βˆTc of the treatment effect β
T
c , c = AUC, Cmax. We
can assume from the theory of mixed effects modeling (see for example Demidenko (2013)) that
this estimate βˆTc is asymptotically normal distributed and following the discussion in Section
2.1 the null hypothesis in (4.8) is rejected whenever
βˆTc − (−δ)
SE(βˆTc )
≥ z1−α and βˆ
T
c − δ
SE(βˆTc )
≤ −z1−α, c = AUC,Cmax, (4.9)
where z1−α is the (1−α)-quantile of the standard normal distribution and SE(βˆTc ) is an estimate
of the standard error of the estimate βˆTc .
We obtain SE(βˆTc ) by using an asymptotic approximation based on the estimated covariance
matrix of the fixed effects (given by a submatrix of the inverse of the Fisher information
matrix) and the Delta-method (see Oehlert (1992) and Dubois et al. (2011) for the concrete
calculation). More precisely, considering (4.7) and denoting the estimated covariance matrix of
the fixed effects by Vˆ , we have
SE(βˆTc ) =
√
∇hc(λˆ, βˆ) · Vˆ · ∇hc(λˆ, βˆ), c = AUC, Cmax, (4.10)
where ∇hc denotes the gradient of the function hc, expressing βTc as a function of the model
parameters (c = AUC or Cmax). As the functions hAUC and hCmax are known, all quantities of
the rejection rule given in (4.9) can be directly obtained from the estimates of the parameters
in model (4.1).
3.3 Model-based optimal Bioequivalence Test
In this section we extend the bioequivalence test described in Section 2.2 to NLMEM. It will
be shown in Section 4 that the new method significantly improves currently used tests for
bioequivalence of concentration curves measured by the pharmacokinetic parameters AUC and
Cmax as it can also be applied in the case of sparse designs. Further this test turns out to be
more powerful than the model-based TOST described in Section 3.2, in particular for small
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sample sizes or data with high variability. The adaption of Algorithm 2.1 to model-based
bioequivalence is very straight forward and is summarized in the following algorithm:
Algorithm 3.1. (A model-based optimal bioequivalence test on AUC and Cmax)
1. Estimate a NLMEM to the data, resulting in the parameter estimate θˆ = (λˆ, βˆ, Ωˆ, Γˆ, aˆ, bˆ).
This can be done for example for parallel designs using the saemix package by Comets
et al. (2011). The test statistic can be directly calculated as secondary parameter of the
model parameters (see (4.7)) and is given by
|βˆTc | = |hc(λˆ, βˆ)|, c = AUC,Cmax.
Approximate the standard error of the estimate SE(βˆTc ), c = AUC,Cmax, by using the
Delta-Method as describred in (4.10).
2. Reject the null hypothesis, whenever
|βˆTc | < uˆα, (4.11)
where uˆα is the α-quantile of the folded normal distribution NF (δ, (SE(βˆTc ))2).
Finite sample properties of this method are given in Section 4.
4 Numerical comparison of NCA- and model-based- ap-
proaches
In this section we investigate the finite sample properties of the different methods by means of a
simulation study. For this purpose we consider eight different scenarios for parallel designs and
for two-periods-two-sequence-cross-over studies respectively. Note that the latter represent the
standard design for bioequivalence trials. More precisely, we will use the models as described in
Section 3.1 in order to simulate pharmacokinetic (PK) data using a population PK model with
several scenarios varying the study design, the number of sampling times per subject n and the
magnitude of BSV and WSV (for the cross-over designs). The threshold for bioequivalence in
(2.1) is as explained in Section 2 chosen as δ = log(1.25) in all cases under consideration.
4.1 Settings
We use the same PK model as described in Dubois et al. (2011), which describes concentra-
tions (mg/l) of the anti-asthmatic drug theophylline, for both reference and test group. More
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precisely, we consider a one-compartment model with first-order absorption and first-order
elimination and hence the pharmacokinetic function f in (4.1) is defined by
f(t,D, ka, CL/F, V/F ) =
F ·D · ka
V (CL
V
− ka)
(
exp(−ka · t)− exp(−CL
V
· t)
)
, (5.1)
where D is the dose, F the bioavailability, ka the absorption rate constant, CL the clearance
of the drug, and V the volume of distribution and hence ψ is composed of ka, CL/F and V/F .
The value for the residual error model in (4.2) were set to a = 0.1mg/l and b = 10%. The dose
is fixed to D = 4mg for all subjects, and the fixed effects for the reference treatment group are
λka = 1.5h
−1, λCL/F = 0.04 l h−1, and λV/F = 0.5 l. The variance-covariance matrices Ω and Γ
were chosen to be diagonal and we investigate two different levels of variability for the parallel
and crossover design as specified in Table 1. To evaluate the type I error of the approaches, we
simulate a treatment effect on parameters V and CL given by βTV = β
T
CL = log(1.25), which
affects the AUC and Cmax similarly, that is |µT − µR| = βTAUC = |log(AUCT )− log(AUCR)| =
βTCmax = |log(CmaxT )− log(CmaxR)| = log(1.25). The power of the bioequivalence test will be
evaluated for βCL = βV = log(1). We will study two sampling time designs
- Rich design: N = 40, n = 10 samples taken at times t = (0.25, 0.5, 1, 2, 3.5, 5, 7, 9, 12, 24)
hours after dosing,
- Sparse design: N = 40, n = 3 samples taken at times t = (0.25, 3.35, 24) hours after
dosing
as described in Dubois et al. (2011), where all subjects have the same vector of sampling times.
Note that in this situation the sparse design reflects the most critical case as three sampling
points are the minimum required for estimating a model with three parameters given in (5.1).
For each scenario, we simulate 500 data sets. For the estimation of the model parameters we use
the SAEM algorithm (see Kuhn and Lavielle (2005)). More precisely, in case of parallel designs,
we use the R package saemix developed by Comets et al. (2011) with 10 chains and (300, 100)
iterations. For crossover studies, we used Monolix 2018 R2 developed by Lixoft (2018) to fit
the model to the data with the same number of chains and interations as for parallel designs.
For the standard NCA analysis (see for example Gabrielsson and Weiner (2001)) we used the R
package MESS developed by Ekstrom (2019). As this technique is not appropriate for sparse
samples we only report results for NCA-based methods based on rich design.
We start considering a parallel design. Two-treatments parallel trials are simulated, that is
20 subjects receive the reference treatment R and the other 20 subjects are allocated to the
test treatment T. Illustrations of the simulated concentrations in groups R and T under H0
and H1 in (4.8) are presented in Figure 1. Secondly, we observe a two-periods two-sequences
crossover design. For each trial, the 20 subjects allocated to the first sequence receive the
reference treatment first and then the test treatment. The other 20 subjects allocated to the
11
Design Variability Scenario ωka ωV/F ωCL/F γka γV/F γCL/F
Parallel
Low BSV 22 11 22 NA NA NA
High BSV 52 NA NA NA
Crossover
Low 20 10 20 10 5 10
High 50 15
Table 1: Simulated values for the parallel and crossover design, low and high variability settings.
ω and γ are expressed as coefficient of variation in %. Entries ”NA” correspond to ”not
applicable”.
second sequence receive treatments in the reverse order. Table 1 displays all variabilities under
consideration.
4.2 Results
4.2.1 Type I error
In Table 2 we show the results for all tests proposed in Sections 2 and 3. For parallel designs
it becomes obvious that both the NCA-based and the model-based TOST are conservative in
settings with a high variability, while the new approach yields a very accurate approximation of
the level. This corresponds to the empirical findings in Section 2 and the theoretical arguments
given in the Appendix. However, we observe a slightly increased type I error for the sparse
design with low variability for both model-based methods, probably due to standard error
underestimation as mentioned by Dubois et al. (2011). For rich samples and low variability all
four tests under consideration perform well and yield an accurate approximation of the nominal
level at boundary of the hypotheses, that is δ = log(1.25).
In the case of crossover designs the approximation of the level is very precise for all four tests
under consideration, even in the case of high variability. This can be explained by the fact that
each individual receives a test and a reference treatment and hence we have twice as much data
as for the parallel designs data. However, there is a slight type I error inflation (0.078) for the
model-based TOST considering a sparse design with high variability. Concluding, the type I
error rates are close to α in almost all scenarios under consideration. For increasing variances
both versions of the TOST become very conservative whereas the new approach approximates
the level still very precisely.
12
Figure 1: Spaghetti plots of simulated concentrations for parallel design with N = 40/n = 10
((a) and (c))) and N = 40/n = 3 ((b) and (d)), low variability under H0 (top line), that is
βT = log(1.25) and H1 (bottom line), that is β
T = log(1). On each plot, profiles on the left
correspond to the reference group (R) and profiles on the right correspond to the treatment group
(T).
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Study Design Parallel Crossover
Sampling time Rich Sparse Rich Sparse
Variability Low High Low High Low High Low High
NCA-TOST
AUC 0.052 0.022 - - 0.046 0.042 - -
Cmax 0.062 0.012 - - 0.062 0.070 - -
NCA-BOT
AUC 0.052 0.054 - - 0.046 0.042 - -
Cmax 0.062 0.052 - - 0.062 0.070 - -
MB-TOST
AUC 0.056 0.004 0.076 0.006 0.056 0.042 0.038 0.050
Cmax 0.058 0.008 0.066 0.002 0.064 0.070 0.044 0.078
MB-BOT
AUC 0.056 0.064 0.076 0.034 0.056 0.044 0.038 0.056
Cmax 0.070 0.060 0.070 0.058 0.064 0.054 0.044 0.056
Table 2: Simulated type I errors of the four tests under H0, where BOT denotes the test derived
in Algorithm 3.1. The numbers in boldface indicate that the type I error falls outside of the
95% prediction interval [0.0326; 0.0729] centered at 0.05.
4.2.2 Power
In order to investigate the power of the proposed methods we consider the scenarios summarized
in Table 1 with a treatment effect of βTAUC = 0 and β
T
Cmax
= 0. In Table 3 we display the results
for the four tests under consideration. In the case of parallel designs we observe that a sparse
design does not affect the performance of the tests as much as the level of variability, which
when high leads to a huge loss of power for all methods. Although in these settings the power
is only close to 0.15 for the new model-based approach, a noticeable improvement compared
to the model-based TOST is visible, as for this test the power is practically zero. For low
variability the model-based tests perform very similarly, which confirms again the empirical
findings in Section 2 and some theoretical explanation for these observations is given in the
appendix. When considering rich designs the NCA-based methods achieve more power than the
model-based ones but the difference turns out to be quite small. However, for sparse designs
NCA-based methods are not applicable and in case of low variability we obtain a very high
power for both model-based approaches. For the cross-over designs all tests under consideration
yield a power of one, irrespective of the sampling time, design and variability. This effect can
again be explained by the larger sample size and each individual receiving both treatments.
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Study Design Parallel Design Crossover Design
Sampling Time Rich Sparse Rich Sparse
Variability Low High Low High Low High Low High
NCA-TOST
AUC 0.998 0.132 - - 1.000 1.000 - -
Cmax 0.998 0.056 - - 1.000 1.000 - -
NCA-BOT
AUC 0.998 0.228 - - 1.000 1.000 - -
Cmax 0.998 0.154 - - 1.000 1.000 - -
MB-TOST
AUC 0.830 0.008 0.804 0.004 1.000 1.000 1.000 0.998
Cmax 1.000 0.024 1.000 0.016 1.000 1.000 1.000 1.000
MB-BOT
AUC 0.838 0.140 0.808 0.132 1.000 1.000 1.000 1.000
Cmax 1.000 0.138 1.000 0.116 1.000 1.000 1.000 1.000
Table 3: Simulated power of the four tests under H1, where BOT denotes the test derived in Algorithm
3.1.
5 Conclusions
In this paper we addressed the problem of sparse designs and high variability in bioequivalence
studies. As described by Phillips (1990) and Tsai et al. (2014) we demonstrated that in general
for data with high variability methods based on the TOST suffer from a lack of power. To
address this problem we introduced a new method using quantiles of the folded normal dis-
tribution, which we called bioequivalence optimal testing in this paper. In the case of known
variances we proved in the Appendix that this test is uniformly most powerful in this setting
and has consequently more power than the TOST. These arguments can be transferred to gen-
eral bioequivalence testing using NCA or NLMEM if the sample variances can be estimated
with reasonable accuracy.
By means of a simulation study we compared the new procedure to the TOST, considering them
both based on NCA and NLMEM. We demonstrated that bioequivalence testing based on the
new approach is a more powerful alternative to the commonly used TOST if the AUC and
Cmax are obtained by NCA. This superiority is also observed if these parameters are obtained
by fitting an NLMEM, in particular for data with large variability.
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A Theoretical comparison of tests for bioequivalence
In this section we provide some theoretical explanation, why the approach presented in Section
2.2 has more power than the TOST. For this purpose we now assume that variances in the
reference and treatment group are known. In this case the quantiles of the t-distribution in
(2.7) can be replaced by those of a normal distribution and the power functions of all tests
can be calculated explicitly. We also note that this assumption is very well justified, if the
sample sizes in both groups are sufficiently large. In other words: all arguments presented in
this section can be applied to the NCA-based tests discussed in Section 2.1 and 2.2 provided
that the sample sizes are sufficiently large. A similar comment applies to the model-based test
for bioequivalence introduced in Section 3. We begin with a discussion of the TOST.
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A.1 The two one-sided Test (TOST)
Consider the rejection rule of the TOST defined in (2.7), where we replace the estimate of the
(pooled) variance σ2P =
σ2
NT
+ σ
2
NR
by its true value and the quantile tN−2,1−α by the (1 − α)
quantile of the standard normal distribution denoted by z1−α. If z1−α > δ/σP the probability
of rejection is 0 (because the conditions in (2.7) are contradicting). On the other hand, and
more importantly, if z1−α ≤ δ/σP the probability of rejection for the test (2.7) is given by
ΨTOST(d) := Pd
(
X¯T−X¯R+δ
σP
≥ z1−α, X¯T−X¯R−δσP ≤ −z1−α
)
= Pd
(
z1−α − δ+dσP ≤
X¯T−X¯R−d
σP
≤ −z1−α + δ−dσP
)
= Φ
(
− z1−α + δ−dσP
)
− Φ
(
z1−α − δ+dσP
)
, (3.1)
where Φ denotes the distribution function of the standard-normal distribution. From this
formula we draw the following conclusions (if z1−α ≤ δ/σP ):
(1) The test (2.7) controls its level. For example, if d > δ we have
ΨTOST(d) < Φ (−z1−α) = α
and with a similar argument the same inequality can be derived for d < −δ.
(2) At the ”boundary” of the null hypothesis (that is d ∈ {−δ, δ}) we have
ΨTOST(±δ) = α− Φ
(
z1−α − 2δσP
)
≤ α,
As Φ
(
z1−α − 2δσP
)
converges to 0 if δ
σP
converges to infinity, we expect that the level of
the test (2.7) is close to α at the ”boundary” of the null hypothesis, if σ is small. This
happens, for example, if the variance σ2 (and hence the pooled variance σ2P ) is small
or, alternatively, if the sample sizes NR and NT in both groups are very large. On the
other hand the test (2.7) is conservative if the variance σ2 is large. In the extreme case
δ
σP
= z1−α we have
ΨTOST(±δ) = α− Φ (−z1−α) = 0.
A.2 The uniformly most powerful approach
Similar to the TOST the test proposed in Section 2.2 simplifies under the additional assumption
of a known variance. As the variance is assumed to be known, the null hypothesis is rejected,
whenever, ∣∣X¯T − X¯R∣∣ < uα, (3.2)
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where uα denotes the α-quantile of the folded normal distribution NF (δ, σ2P ). The following
result shows that the test defined by (2.8) is the uniformly most powerful test for the hypotheses
(2.1). It is well known in the mathematical statistics literature and we present a proof here
for the sake of completeness (see also Lehmann and Romano (2006), Romano et al. (2005) or
Wellek (2010)).
Theorem A.1. The test defined by (2.8) is the uniformly most powerful (UMP) for the hypothe-
ses (2.1). Moreover, among all tests for the hypotheses (2.1) with power function Ψ satisfying
Ψ(δ) = Ψ(−δ) = α the test defined by (2.8) has also minimal type I error.
Proof: In order to prove optimality recall (2.5), that is X = X¯T − X¯R ∼ N (d, σ2P ), and note
that the hypotheses in (2.1) can be rewritten as
H0 : |d| ≥ δ vs. H1 : |d| < δ . (3.3)
The test (2.8) rejects the null hypothesis whenever
∣∣X¯R − X¯T ∣∣ < uα, where uα is the quantile
of the folded normal distribution with parameters (δ, σ2P ), which is defined by
α = P
(∣∣N (δ, σ2P )∣∣ ≤ uα) = Φ( 1σP (uα − δ))− Φ( 1σP (−uα − δ)) . (3.4)
The probability of rejection is now given by
Pd(
∣∣X¯T − X¯R∣∣ < uα) = Pd(−uα < X¯T − X¯R < uα)
= Pd
(
1
σP
(−uα − d) < X¯T−X¯R−dσP < 1σP (uα − d)
)
= Φ
(
1
σP
(uα − d)
)
− Φ
(
1
σP
(−uα − d)
)
, (3.5)
where Φ denotes the distribution function of the standard-normal distribution.
On the other hand the uniformly most powerful test for the problem (3.3) is well known, see for
example Theorem 6 in Section 3.7 of Lehmann and Romano (2006) or Example 1.1 in Romano
et al. (2005) This test reject the null hypothesis in (3.3), whenever
|X¯T − X¯R| < C
where the constant C = C(α, δ, σP ) is the unique solution of the equation
α = Φ
(
1
σP
(C − δ)
)
− Φ
(
1
σP
(−C − δ)
)
(3.6)
[see Example 1.1 in Romano et al. (2005)]. As the equations (3.4) and (3.6) coincide, it follows
that uα = C and the test (2.8) coincides with the UMP test for the hypotheses (2.1). 2
As a consequence of Theorem A.1 the test proposed in Section 2.2 has always more power than
the test defined by (2.7). This is indicated in Figure 2, where we display the power of both
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tests in different scenarios (α = 0.05, δ = log(1.25)). The left panel shows the power curves for
σ2P = 0.0049. In this case the curves basically coincide (although the power of the test (2.8)
is slightly larger as stated in Theorem A.1). For increasing variance (σ2P = 0.0144) it becomes
obvious that the power of the test (2.8) is much higher than that for the TOST. This effect
becomes even clearer in the right panel (σ2P =
( log(1.25)
z1−α
)2 ≈ 0.142), where the power curve of
the TOST is identical to zero.
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Figure 2: Power curves of the tests (2.8) (solid red line) and the test (2.7) (dashed line) for
different σP = 0.07, σP = 0.12 and σP =
log(1.25)
z1−α
≈ 0.14 (from left to right). The horizontal
line indicates the level α = 0.05 and the vertical lines mark the threshold (±δ = ±log(1.25)).
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